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Alcohol dementia (ALD) usually follows long-term alcohol de-
pendence. The major psychiatric features of ALD are general loss of
short- and long-term memory combined with disturbances in con-
centration and a decrease in intellectual capacity, all of which persist
during abstinence. Despite its clinical importance, few studies have
been published up to now on medical treatment of ALD and other
alcohol-induced mental disorders [1]. The central nervous gluta-
matergic system, with its N-methyl-D-aspartate (NMDA) receptors,
is suggested to be involved in toxic neuronal loss [2] due to an
increased glutamatergic neurotransmission during repeated alcohol
withdrawal and may subsequently contribute to the development of
ALD. The low-affinity NMDA receptor antagonist memantine (ada-
mantine, 1-amino-3,5-dimethyladamantine hydrochloride, CAS
41100-52-1) modulates the glutamatergic system most likely through
Ca2+ influx blockage of NMDA receptors [3] and shows positive
effects on memory in the treatment of other psychogeriatric disorders
with memory loss such as Alzheimer’s dementia (AD) or Parkinson’s
disease [4].
We would like to report the case of a 71-year-old female patient
with chronic alcoholism for at least 30 years. She was found neglected
in her home and was admitted to our ward from an emergency unit
with symptoms of disorientation, apraxia, ataxia, severe short- and
long-term memory disturbances, deficits in intellectual capacity and
concentration. There were no signs of electrolyte imbalance on
admission. A further thorough neurological investigation and NMR
showed a general atrophy without severe basal brain damage of Wer-
nicke encephalopathy. No other signs of Wernicke encephalopathy,
i.e. ophthalmoplegia or evidence of hepatic encephalopathy such as
flapping tremor, were found. Ultrasound of brain arteries showed
some plaques without hemodynamic compromise. After excluding
Alzheimer’s disease or vascular dementia, the diagnosis of ALD
according to ICD10 criteria was made.
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Fig. 1. FDG-PET 1 week after admission (study 1) and 5 weeks after starting the memantine treatment (study 2). The
initial study showed a bilateral, symmetrical decrease in regional cerebral glucose consumption involving the frontal,
parietal and temporal lobes. The second study, performed 5 weeks later, revealed a nearly normal pattern of glucose
metabolism.
We started treatment with memantine for 5 weeks with a dosage
up to a maximum of 30 mg/day to improve memory and intellectual
capacity. The patient was neuropsychologically tested before and
retested after 5 weeks of treatment employing the same psychological
tests. Improvement was seen in MMSE (Mini-Mental State Exami-
nation) [5] from 18 to 22 points, and CERAD Verbal Fluency (Con-
sortium to Establish a Registry for Alzheimer’s Disease) [6] from 10
to 12 points. CERAD Wordlist Recall improved from 0 to 5 and
CERAD Drawing from 6 to 8.
Parallel to psychological testing, an 18F-fluorodeoxyglucose-posi-
tron emission tomography (FDG-PET) was performed 1 week after
admission and 5 weeks after starting the memantine treatment, as
extensively described elsewhere [7]. The initial study revealed a bilat-
eral, symmetrical decrease in regional cerebral glucose consumption
involving the frontal lobes and extended areas of the parietal and
temporal lobes. The second study, performed 5 weeks later, revealed
a nearly normal pattern of glucose metabolism (fig. 1). However,
despite these findings and improvement of some intellectual and
memory functions, severe memory deficits and disorientation per-
sisted. The patient was recommended for continued inpatient care
but no deterioration of the mental abilities was observed even 1 year
after discharge.
This is the first report on memantine treatment in an ALD
patient. To our knowledge, this is also the first report on FDG-PET
in an ALD patient. Significant changes in cerebral blood flow after
5 weeks of memantine treatment were revealed using FDG-PET,
which were paralleled by moderate improvements in neuropsycho-
logical testing. It supports the hypothesis that low-affinity NMDA
antagonists have a neuroprotective effect even in manifest ALD
patients [3, 4].
The PET findings prior to the memantine treatment were very
similar to those in patients with AD. Both AD and ALD can be diag-
nosed after excluding other kinds of dementia and their FDG-PET
findings may be similar. In our case, a 33-year history of severe alco-
hol intake was reported. The clinical course in AD is deteriorating
over time whereas the mental abilities in this case remained stable
under abstinent conditions and even improved slightly. This is very
untypical for ALD. Furthermore, a well-known phenomenon is a
spontaneous improvement in mental abilities in patients suffering
from Korsakoff’s syndrome or ALD [8]. This could not be proven in
this case report. Thus, larger, controlled double-blind trials with this
agent in ALD patients are needed to evaluate the use of memantine
in alcohol-induced dementia syndromes.
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